Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (17547)	3/17/1998 7:03:00 PM
From: Flagrante Delictu	Respond to of 32384

tuck, Re: the LLY compound. David Robinson talked about a compound that would yield $50 million in sales at a royalty to Lilly of 10% & other costs, presumably manufacturing of the compound, of around 10% additional, leaving 80% gross margins for LGND. That's why the guess was the SRGN compound. To get $50 million sales in Canada would require a substantial boost in the salesforce there & would be contra-indicated by the expected U.S. sales force estimate of 16. Bernie.

To: tuck who wrote (17547)	3/17/1998 7:04:00 PM
From: Hippieslayer	Respond to of 32384

I think LGND is trying to renig on the whole LLY deal in order to get the stock back to where it was before the deal!!! Just kidding. For a company that is suppose to be the next best thing since sliced bread, they are sure dragging their feet. We still wait for the leptin deal AND the lly drug AND the NDA, and............